• Orthocell granted Chinese patent for method to manufacture Celgro™ collagen medical device platform technology
• Patent relates to manufacture of novel bio-scaffolds to aid in the surgical repair of soft tissue injuries to tendons, cartilage and eardrums, and the delivery of stem cells to the surgical site
• Orthocell has previously been granted patents for this method in Singapore and New Zealand
Perth, Australia; 15th January 2015: Regenerative medicine company Orthocell Limited has today announced it has been granted a Chinese patent covering the manufacture of biological materials to repair damaged soft tissue.
The patent, described as “Chinese patent # CN 102159256 B Entitled: A Collagen Scaffold for Cell Growth and a method producing the Same (PCT/AU2008/000583)”, relates to Orthocell’s CelgroTM product.
“This comes at a perfect time for the company as we move our products through international registration processes,” Orthocell Managing Director Paul Anderson said.
“It further strengthens our global intellectual property position for our unique regenerative therapies.”
Orthocell’s novel methodology for producing a bio-scaffold device overcomes or alleviates some of the major problems associated with other currently available bio-scaffolds which can include:
• poor surface chemistry which provides suboptimal attachment of cells;
• acidic by-products which degrade the local pH such that cell micro-environments are disrupted;
• immune reactions due to presence of residual foreign cells from the host and;
• lack of suitable pore size and structure and lack of sufficient mechanical properties required to withstand the harsh environments in which bio-scaffolds are regularly used.
The company’s CelgroTM technology is a next-generation collagen-based scaffold to support tissue growth and repair. Its unique characteristics include:
• cell free matrix that is devoid of contaminants and reactive DNA;
• tissue friendly structure that facilitates tissue in-growth and repair;
• mechanical strength and pliability for tissue support during healing;
• Australian-sourced raw materials able to be reproduced in large commercial quantities thus eliminating disease transmission concerns.
“We believe CelgroTM collagen scaffold products are superior to other existing collagen products and offer widespread therapeutic and commercial potential with particular emphasis on orthopaedic and reconstructive applications, such as tendon, bone and soft tissue defect repair,” Mr Anderson said.
The CelgroTM technology platform has been validated by Orthocell’s recent partnership with world-leading bone substitute firm BONESUPPORT to use CelgroTM to create new bone repair products.
For more information, please contact:
General enquiries
Paul Anderson
Orthocell Limited, Managing Director
P: (08) 9360 2888
E: paulanderson@orthocell.com.au
Media enquiries
Gavin Lower
Buchan Consulting
P: (03) 8866 1215 / 0414 796 726
E: glower@buchanwe.com.au
Investor Relations
Rebecca Wilson
Buchan Consulting
P: 0417 382 391
E: rwilson@buchanwe.com.au
About Orthocell Limited
Orthocell is a commercial-stage, regenerative medicine company focused on developing products for a variety of tendon, cartilage and soft tissue injuries. Orthocell’s portfolio of products include TGA-approved stem cell therapies Autologous Tenocyte Implantation (Ortho-ATI™) and Autologous Chondrocyte Implantation (Ortho-ACI™), which aim to regenerate damaged tendon and cartilage tissue. The Company’s other major product is Celgro™, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications and is being readied for first regulatory approvals.
Help employers find you! Check out all the jobs and post your resume.
